tirzepatide death Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

GROUNDBREAKING UPDATE! FDA has approved TIRZEPATIDE, a pioneering obesity treatment activating GIP & GLP-1 receptors, for weight loss! Previously, Tirzepatide has been FDA approved for type 2 diabetes as Mounjaro, and although

21.57

★★★★☆4.8 (126)

Tirzepatide Matches Dulaglutide in Heart Protection and Cuts Death Risk in Diabetes Trial

28.92

★★★★★4.9 (98)

🚨 New real-world data from #ESC2025: 📉 semaglutide 2.4 mg cuts risk of heart attack, stroke or death by 57% vs. tirzepatide in people with obesity & CVD. 🧬 Benefits appear specific

29.78

★★★★★5.0 (157)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

28.83

★★★★★4.7 (84)

Weight-Loss Drug Reduces Risk of Early Death for Patients with Heart Failure

24.75

★★★★★4.9 (203)

Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study

27.80

★★★★★5.0 (176)

Stopping GLP-1 drugs can quickly erase cardiovascular benefits | Office of Neuroscience Research

22.82

★★★★★4.8 (132)